These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 21390279)

  • 1. Application of biomarkers in cancer risk management: evaluation from stochastic clonal evolutionary and dynamic system optimization points of view.
    Li X; Blount PL; Vaughan TL; Reid BJ
    PLoS Comput Biol; 2011 Feb; 7(2):e1001087. PubMed ID: 21390279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatic clonal evolution: A selection-centric perspective.
    Scott J; Marusyk A
    Biochim Biophys Acta Rev Cancer; 2017 Apr; 1867(2):139-150. PubMed ID: 28161395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New cancer biomarkers deriving from NCI early detection research.
    Verma M; Srivastava S
    Recent Results Cancer Res; 2003; 163():72-84; discussion 264-6. PubMed ID: 12903844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated proteo-genomic approach for early diagnosis and prognosis of cancer.
    Shukla HD; Mahmood J; Vujaskovic Z
    Cancer Lett; 2015 Dec; 369(1):28-36. PubMed ID: 26276717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A risk management approach for imaging biomarker-driven clinical trials in oncology.
    Liu Y; deSouza NM; Shankar LK; Kauczor HU; Trattnig S; Collette S; Chiti A
    Lancet Oncol; 2015 Dec; 16(16):e622-8. PubMed ID: 26678215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Status of Immune Oncology: Challenges and Opportunities.
    Cesano A; Marincola FM; Thurin M
    Methods Mol Biol; 2020; 2055():3-21. PubMed ID: 31502145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances for studying clonal evolution in cancer.
    Ding L; Raphael BJ; Chen F; Wendl MC
    Cancer Lett; 2013 Nov; 340(2):212-9. PubMed ID: 23353056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extracting biomarkers of commitment to cancer development: potential role of vibrational spectroscopy in systems biology.
    Theophilou G; Paraskevaidi M; Lima KM; Kyrgiou M; Martin-Hirsch PL; Martin FL
    Expert Rev Mol Diagn; 2015 May; 15(5):693-713. PubMed ID: 25804575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer screening: a mathematical model relating secreted blood biomarker levels to tumor sizes.
    Lutz AM; Willmann JK; Cochran FV; Ray P; Gambhir SS
    PLoS Med; 2008 Aug; 5(8):e170. PubMed ID: 18715113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer Biomarkers Discovery and Validation: State of the Art, Problems and Future Perspectives.
    Mordente A; Meucci E; Martorana GE; Silvestrini A
    Adv Exp Med Biol; 2015; 867():9-26. PubMed ID: 26530357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variability in the Solid Cancer Cell Population and Its Consequences for Cancer Diagnostics and Treatment.
    Brychtová V; Valík V; Vojtěšek B
    Klin Onkol; 2018; 31(Suppl 2):5-13. PubMed ID: 31023018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic and Predictive Biomarkers in Cancer.
    Nair M; Sandhu SS; Sharma AK
    Curr Cancer Drug Targets; 2014; 14(5):477-504. PubMed ID: 24807144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study.
    Takahashi K; Wang F; Kantarjian H; Doss D; Khanna K; Thompson E; Zhao L; Patel K; Neelapu S; Gumbs C; Bueso-Ramos C; DiNardo CD; Colla S; Ravandi F; Zhang J; Huang X; Wu X; Samaniego F; Garcia-Manero G; Futreal PA
    Lancet Oncol; 2017 Jan; 18(1):100-111. PubMed ID: 27923552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteomics in cancer research: Are we ready for clinical practice?
    Maes E; Mertens I; Valkenborg D; Pauwels P; Rolfo C; Baggerman G
    Crit Rev Oncol Hematol; 2015 Dec; 96(3):437-48. PubMed ID: 26277237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Not Everyone Fits the Mold: Intratumor and Intertumor Heterogeneity and Innovative Cancer Drug Design and Development.
    Dzobo K; Senthebane DA; Thomford NE; Rowe A; Dandara C; Parker MI
    OMICS; 2018 Jan; 22(1):17-34. PubMed ID: 29356626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers.
    Moosavi F; Giovannetti E; Saso L; Firuzi O
    Crit Rev Clin Lab Sci; 2019 Dec; 56(8):533-566. PubMed ID: 31512514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early detection of cancer: past, present, and future.
    Schiffman JD; Fisher PG; Gibbs P
    Am Soc Clin Oncol Educ Book; 2015; ():57-65. PubMed ID: 25993143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive and prognostic biomarkers in colorectal cancer: A systematic review of recent advances and challenges.
    Das V; Kalita J; Pal M
    Biomed Pharmacother; 2017 Mar; 87():8-19. PubMed ID: 28040600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytogenetics and Cytogenomics Evaluation in Cancer.
    Ribeiro IP; Melo JB; Carreira IM
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31547595
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.